
Mirdametinib Represents Long-Awaited Approved Treatment Option for Adult NF1-Associated PNs
The FDA approval of mirdametinib (Gomekli) marked a key milestone for adult patients with neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PNs), with an agent now indicated for the treatment of this population for the first time, …